ACUTE LEUKEMIAS XVII
Biology and Treatment Strategies

Munich, Germany - February 24-27, 2019

International Symposium

Industry Sponsored Satellite Symposia

(Companies in alphabetical order)

 

Amgen GmbH (Gold Circle Member)

Satellite Symposium II: Sunday, February 19, 2017: 18.15 -19.15 (Lecture Hall III/IV)

"Novel Treatment Strategies in Acute Leukemias: The Evolving Role of Immunotherapy"

18.15-18.45
M. Subklewe, Munich, DE
CE33 BiTE

18.45-19.15
N. Gökbuget, Frankfurt, DE
CD19 BiTE in ALL

Remarks and Conclusion

 

Celgene GmbH (Gold Circle Member)

Satellite Symposium VI: Tuesday, February 21, 2017: 16.30 - 17.30 (Lecture Hall III/IV)

"Upcoming Frontiers in the Treatment of AML"

Chair:
W. Hiddemann, Munich, DE

Opening:
W. Hiddemann, Munich, DE

16.35-17.00
Groenbeck, K., Copenhagen, DK
A Rationale for Combining DNA Hypomethylators with Checkpoint Inhibitors in Myeloid Malignancies

17.00-17.25
Thol, F., Hannover, DE
Key Epidemiological and Clinical Findings in AML Patients with IDH Mutations

Remarks and Conclusion

 

Immune Pharmaceuticals (Gold Circle Member)

Satellite Symposium III: Monday, February 20, 2017: 12.45 - 13.45 (Lecture Hall III/IV)

"Reinforcing the Efficacy of Immunotherapy for the Maintenance of remission in AML with Ceplene"

Chair:
W. Hiddemann, Munich, DE

Opening Remarks:
W. Hiddemann, Munich, DE

12.50-13.10
K. Hellstrand, Gothenburg, SE
Role of Cytotoxic T Cells in Remission Maintenance with Ceplene/IL-2 Therapy in AML

13.10-13.15
Discussion

13.15-13.40
Rowe, J., Jerusalem, IL
Maintenance Therapy in AML

13.40-13.45
Discussion

 
Janssen Pharmaceutica NV (Gold Circle Member)

Satellite Symposium V: Monday, February 20, 2017: 18.15 - 19.15 (Lecture Hall III/IV)

"Raising the Bar in AML: Novel Endpoints and New Treatment Approaches"

Chair:
W. Hiddemann, Munich, DE

Learning Objectives:
After participating in this Symposium you should be able to:

  • Explain the Importance of MRD Assessment in AML Clinical Trials in improving Patient Outcomes
  • Describe the Main Immunotherapy Targets in AML and the Rationale for the Use of these Agents

18.15 Introduction
W. Hiddemann, Munich, DE

18.25
G. Ossenkoppele, Amsterdam, NL
Utility of MRD Assessment in AML

18.40 Panel Discussion

18.55
G. Roboz, New York, NY, USA
Future Treatment Options for Patients with AML: A Focus on Immunotherapy

19.05 Panel Discussion

 

Jazz Pharmaceuticals Germany GmbH (Gold Circle Member)

Satellite Symposium VII: Tuesday, February 21, 2017: 17.45 - 18.45 (Lecture Hall III/IV)

"New Perspectives in AML"

Chair:
W. Hiddemann, Munich, DE

Introduction:
W. Hiddemann, Munich, DE

17.50-18.10
U. Krug, Leverkusen, DE
How can we Optimize 7+3?

18.10-18.30
H. Kantarjian, Houston, TX , USA
How can we Expand 7+3?

18.30-18.45
Summary and Final Discussion
W. Hiddemann, Munich, DE

 

SHIRE GmbH (Gold Circle Member)

Satellite Symposium I: Sunday, February 19, 2017: 17.00 - 18.00 (Lecture Hall III/IV)

"Rare Diseases in Hematology"

Chair:
W. Hiddemann, Munich, DE

17.00-17.20
M. Griesshammer, Minden, DE
Therapeutic Options of Essential Thrombocythemia and Perspectives

17.20-17.40
A. Zimran, Jerusalem, IL
Why Hematologists Should Care about Gaucher Disease

17.40-18.00
N. Gökbuget, Frankfurt, DE
Experience with PEG-Asparaginase in Adult ALL

Remarks and Conclusion

 

TEVA GmbH (Gold Circle Member)

Satellite Symposium IV: Monday, February 20, 2017: 16.30 - 18.00 (Lecture Hall III/IV)

"Diagnosis and Management of APL: Teva Young Hematologists Award"

Co-Chairs:
P. Fenaux, Bobigny, F
R.F. Schlenk, Heidelberg, DE

16:30–16:35
Welcome and Introduction
Chair: Pierre Fenaux, France

16:35–16:50
APL: From Worst Prognosis to Best Outcome
Pierre Fenaux, France

16:50–17:05
Best Abstract Presentation 1
(Includes 3 minutes for Q&A)

17:05–17:20
Best Abstract Presentation 2
(Includes 3 minutes for Q&A)

17:20–17:35
Best Abstract Presentation 3
(Includes 3 minutes for Q&A)

17:35–17:50
Best Abstract Presentation 4
(Includes 3 minutes for Q&A)

17:50–18:00
Conclusions
Chair: Richard Schlenk, Germany